Common side effects may include nausea, vomiting, diarrhea, and abdominal pain
Comparison with Similar Peptides GHK-Cu (Current) Half-Life:~2 hours Dosage:1-2 mg daily Administration:Topical or subcutaneous Research Status: Preclinical/Experimental Half-Life:~4 hours Dosage:200-500 mcg daily Administration:Subcutaneous injection Research Status: Preclinical/Experimental Half-Life:~2-3 days Dosage:2-5 mg per week Administration:Subcutaneous injection Research Status: Preclinical/Experimental Half-Life:~2-3 hours Dosage:2-4 IU daily Administration:Subcutaneous injection Research Status: FDA Approved (for specific conditions) Half-Life:~24 hours Dosage:10-25 mg daily Administration:Oral Research Status: Experimental Half-Life:~12 minutes Dosage:1-2 mg daily Administration:Subcutaneous injection Research Status: FDA Approved (for specific conditions) Highlighted rowcard shows the current peptide
Last reviewed: May 12, 2026 Last updated: May 12, 2026 Written by: Jay Hastings, CEO of PlexusDx Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations
Always consult a licensed provider before use
1,2 These activities are constantly challenged by intrinsic and extrinsic perturbations, including increased protein synthesis, ER-Ca 2+ depletion, dysregulated redox homeostasis, energy deprivation, hypoglycemia, hypoxia, and inflammatory stimuli, resulting in improper protein conformation and misfolding, often referred to as nonnative or aberrant conformation
